Publications by authors named "K K Reichard"
The clinical relevance of TP53 mutations (TP53) in myeloproliferative neoplasms (MPN) and their prognostic interaction with MPN subtype designation has not been systematically studied. In the current study, 114 patients with MPN harboring TP53 (VAF ≥ 2%) were evaluated for overall survival (OS), calculated from the time of TP53 detection: chronic phase myelofibrosis (MF-CP; N = 61); blast-phase (MPN-BP; N = 31) or accelerated-phase (MPN-AP; N = 16) MPN, and polycythemia vera/essential thrombocythemia (PV/ET; N = 6). Sixty-five (57%) patients harbored International Consensus Classification (ICC)-defined multihit TP53 and 56 (49%) monosomal/complex karyotype (MK/CK).
View Article and Find Full Text PDFArticle Synopsis
- The obesity epidemic has increased the need for metabolic and bariatric surgery (MBS) among adolescents, but there's limited data on the effectiveness of Enhanced Recovery After Surgery (ERAS) protocols for improving outcomes.
- A comprehensive ERAS pathway was implemented for adolescents undergoing laparoscopic sleeve gastrectomy (LSG), focusing on pre-operative carbohydrate loading, pain management, and early mobilization; various outcome measures were tracked.
- Results showed that the post-ERAS group had significant improvements in time to oral intake, lower usage of rescue anti-emetics, and shorter hospital stays compared to the pre-ERAS group, while overall opioid use and post-operative pain levels remained unaffected.
Vasculitis associated with VEXAS syndrome.
Rheumatology (Oxford)
October 2024
Article Synopsis
- The study aimed to assess the prevalence and characteristics of vasculitis in patients diagnosed with VEXAS syndrome, confirmed through UBA1 mutation.
- A total of 89 male patients with an average age of nearly 67 years were evaluated, with 23.6% showing signs of vasculitis, predominantly small vessel types.
- Findings suggest that VEXAS syndrome can present with vasculitis-related symptoms, including cranial issues that may resemble other conditions like giant cell arteritis, though significant large vessel involvement is infrequent.
This phase 2 trial assessed high-dose IV ascorbic acid in TET2 mutant clonal cytopenia. Eight of 10 patients were eligible for response assessment, with no responses at week 20 by International Working Group Myelodysplasia Syndromes/Neoplasms criteria. This trial was registered at www.
View Article and Find Full Text PDF